Stockreport

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Inc.  (CNTX) 
PDF Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2 [Read more]